International Journal of Hematology

, Volume 107, Issue 4, pp 460–467 | Cite as

Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma

  • Shinsuke Iida
  • Tatsuo Ichinohe
  • Atsushi Shinagawa
  • Kenshi Suzuki
  • Naoki Takezako
  • Masayuki Aoki
Original Article


Daratumumab in combination with bortezomib and dexamethasone (DVd) has demonstrated longer progression-free survival than combination of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (RRMM). In this multicenter, open-label, phase-1 study, the safety, efficacy, and pharmacokinetics (PK) of DVd were evaluated in Japanese patients with RRMM. Eight patients with RRMM aged between 54 and 82 years were enrolled and treated with DVd regimen. Primary endpoints were tolerability and safety. Secondary endpoints were overall response rate (ORR), very good partial response (VGPR) or better, complete response (CR) or better, time to response (TTR), PK, and immunogenicity. All patients (n = 8) experienced Grade ≥ 3 treatment-emergent adverse events (TEAE), with thrombocytopenia (n = 6, 75%) being the most frequent. Mild Grade ≤ 2 infusion-related reactions were reported in five patients. Serious TEAEs were herpes zoster, nasopharyngitis, and prostate cancer (n = 1 each). Three dose-limiting toxicities were observed in two patients. No death or disease progression was reported as of the study cut-off date. ORR was 100% (2 CRs or better, 2 VGPRs, 4 PRs). The median TTR was 0.9 months. PK profiles were comparable to previous studies. The DVd regimen showed acceptable safety with favorable efficacy in Japanese patients with RRMM.

Clinical trial registration number



Daratumumab Efficacy Multiple myeloma Safety Tolerability 


Author contributions

Dr. Aoki had primary role in the study design, analysis and data interpretation. Drs Iida, Ichinohe, Shinagawa, Suzuki and Takezako were involved in study design, data interpretation and also involved as investigators. All authors contributed to the development of the manuscript and approved the final manuscript for submission. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.


This study was sponsored by Janssen Research & Development, LLC.

Supplementary material

12185_2017_2390_MOESM1_ESM.docx (17 kb)
Supplementary material 1 (DOCX 16 kb)


  1. 1.
    Raedler LA. Darzalex (Daratumumab): first anti-CD38 monoclonal antibody approved for patients with relapsed multiple myeloma. Am Health Drug Benefit. 2016;9(Spec Feature):70–3.Google Scholar
  2. 2.
    Ozaki S, Handa H, Saitoh T, Murakami H, Itagaki M, Asaoku H, et al. Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma. Blood Cancer J. 2015;5:e349.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046–60.CrossRefPubMedGoogle Scholar
  4. 4.
    Yoshizawa K, Mukai HY, Miyazawa M, Miyao M, Ogawa Y, Ohyashiki K, et al. Bortezomib therapy-related lung disease in Japanese patients with multiple myeloma: incidence, mortality and clinical characterization. Cancer Sci. 2014;105:195–201.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906–17.CrossRefPubMedGoogle Scholar
  6. 6.
    Sonneveld P, Goldschmidt H, Rosiñol L, Bladé J, Lahuerta JJ, Cavo M, et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol. 2013;31:3279–87.CrossRefPubMedGoogle Scholar
  7. 7.
    Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017;31:2443–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Kumar N, Zaw AS, Reyes MR, Malhotra R, Wu PH, Makandura MC, et al. Versatility of percutaneous pedicular screw fixation in metastatic spine tumor surgery: a prospective analysis. Ann Surg Oncol. 2015;22:1604–11.CrossRefPubMedGoogle Scholar
  9. 9.
    Laubach JP, Voorhees PM, Hassoun H, Jakubowiak A, Lonial S, Richardson PG. Current strategies for treatment of relapsed/refractory multiple myeloma. Expert Rev Hematol. 2014;7:97–111.CrossRefPubMedGoogle Scholar
  10. 10.
    Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128:384–94.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387:1551–60.CrossRefPubMedGoogle Scholar
  12. 12.
    Approved drugs—daratumumab (DARZALEX). Accessed 17 May 2017.
  13. 13.
    Janssen Biotech Inc. DarzalexTM (daratumumab): prescribing information. 2016. Accessed 17 May 2017.
  14. 14.
    Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:754–66.CrossRefPubMedGoogle Scholar
  15. 15.
    Iida S, Suzuki K, Kusumoto S, Ri M, Tsukada N, Abe Y, et al. Safety and efficacy of daratumumab in japanese patients with relapsed or refractory multiple myeloma: a multicenter, phase 1, dose-escalation study. Int J Hematol. 2017;106:541–51.CrossRefPubMedGoogle Scholar
  16. 16.
    Durie BGM, Harousseau J-L, Miguel JS, Bladé J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–73.CrossRefPubMedGoogle Scholar
  17. 17.
    Rajkumar SV, Harousseau J-L, Durie B, Anderson KC, Dimopoulos M, Kyle R, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117:4691–5.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    de Weers M, Tai Y-T, van der Veer MS, Bakker JM, Vink T, Jacobs DCH, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186:1840–8.Google Scholar
  19. 19.
    Kropff MH, Bisping G, Wenning D, Volpert S, Tchinda J, Berdel WE, et al. Bortezomib in combination with dexamethasone for relapsed multiple myeloma. Leuk Res. 2005;29:587–90.CrossRefPubMedGoogle Scholar
  20. 20.
    Dimopoulos MA, Orlowski RZ, Facon T, Sonneveld P, Anderson KC, Beksac M, et al. Retrospective matched-pair analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma. Haematologica. 2015;100:100–6.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Moreau P, San Miguel J, Ludwig H, Schouten H, Mohty M, Dimopoulos M, et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(suppl_6):vi133–7.PubMedGoogle Scholar
  22. 22.
    Mateos M-V, Moreau P, Comenzo R, Bladé J, Benboubker L, de La Rubia J, et al. An open-label, multicenter, phase 1B study of daratumumab in combination with pomalidomide-dexamethasone and with backbone regimens in patients with multiple myeloma. European Hematology Association; 2015. Abstract p. 275.Google Scholar
  23. 23.
    Endell J, Samuelsson C, Boxhammer R, Strauss S, Steidl S. Effect of MOR202, a human CD38 antibody, in combination with lenalidomide and bortezomib, on bone lysis and tumor load in a physiologic model of myeloma. J Clin Oncol. 2011;29: 2011 (suppl; abstr 8078) suppl; abstr 8078. Accessed 17 May 2017.
  24. 24.
    van der Veer MS, de Weers M, van Kessel B, Bakker JM, Wittebol S, Parren PWHI, et al. The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies. Blood Cancer J. 2011;1:e41.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373:1207–19.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2017

Authors and Affiliations

  • Shinsuke Iida
    • 1
  • Tatsuo Ichinohe
    • 2
  • Atsushi Shinagawa
    • 3
  • Kenshi Suzuki
    • 4
  • Naoki Takezako
    • 5
  • Masayuki Aoki
    • 6
  1. 1.Department of Hematology and OncologyNagoya City University Graduate School of Medical SciencesNagoyaJapan
  2. 2.Department of Hematology and Oncology, Research Institute for Radiation Biology and MedicineHiroshima UniversityHiroshimaJapan
  3. 3.Hitachi General HospitalHitachiJapan
  4. 4.Department of HematologyJapanese Red Cross Medical CenterTokyoJapan
  5. 5.Department of HematologyNational Disaster Medical Center of JapanTokyoJapan
  6. 6.Janssen Pharmaceutical K.K.TokyoJapan

Personalised recommendations